Press ReleaseApr 18, 2023
Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

New launch of Mounjaro® 2.5 mg / 5 mg Ateos®,
the world’s first sustained release GIP/GLP-1 receptor agonist
April 18, 2023 - Eli Lilly Japan K.K. (Head Office: Kobe, Japan, Representative Director and President:
Simone Thomsen, hereinafter called “Eli Lilly Japan”) and Mitsubishi Tanabe Pharma Corporation(Head Office: Osaka, Japan, Representative Director: Akihiro Tsujimura, hereinafter called “MTPC”) announced that “Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®” (Non-proprietary name: Tirzepatide, hereinafter referred called “Mounjaro”), the following sustained release GIP/GLP-1 receptor
agonists, was launched in Japan today.
As the world’s first sustained release GIP (glucose-dependent insulinotropic polypeptide) and GLP-1(glucagon-like peptide-1) receptor agonist, Mounjaro activates two receptors: GIP and GLP-1. Although
the structure of Mounjaro is a single molecule based on the natural GIP peptide sequence, it has been
modified to also bind to the GLP-1 receptor, and selectively acts for a long time to improve blood glucose.
Mounjaro is administered once weekly by subcutaneous injection with a single-use autoinjector device(ATEOS). Using a special pen injector with a pre-installed needle, the needle is automatically inserted
under the skin by pressing the injection button, and a single dose of the filled drug is injected. The patientdoes not need to set the dose or handle the needle.
The usual starting dose for adults is 2.5 mg of tilzepatide once a week for 4 weeks, after which the doseis increased to a maintenance dose of 5 mg once a week. Of the six dose standards, two, the starting
dose (2.5 mg) and the maintenance dose (5 mg), were launched earlier today. The higher four dose
(7.5 mg, 10 mg, 12.5 mg, and 15 mg) are scheduled for launch on June 12, 2023.
Eli Lilly and Company obtained an approval of Mounjaro in the United States on May 13, 2022 as theworld’s first sustained release GIP/GLP-1 receptor agonist and launched it on June 7, 2022. In Japan,
Mounjaro was also approved on September 26, 2022. Eli Lilly Japan holds the manufacturing and marketing approval for Mounjaro, while MTPC is responsible for sales and distribution. Eli Lilly Japan andMTPC will jointly provide information to healthcare professionals.
“We are very pleased to announce the launch of Mounjaro. We will strive to provide appropriate information so that we can deliver Mounjaro as a new class of treatment options to many people living withtype 2 diabetes who need it.,” said Mary Thomas, Associate Vice President, Diabetes and Growth Hormone Business unit, Eli Lilly Japan.

1/3

“MTPC sets the MISSION of ‘Creating hope for all facing illness.’ We will continue to promote theproper use through information provision activities so that Mounjaro, which was launched today, will bea hopeful option for people living with type 2 diabetes.,” said Katsunori Yoshinaga, Head of Sales &Marketing Division, MTPC.
Reference Information

Product Summary
Product Name

Non-proprietary Name
Indications
Dosage andAdministration

Date of acquisition ofmanufacturing and marketing approval
Date of NHI price listing
Date of launch
Drug price
Manufacturer and distributor
Distributor

Mounjaro® subcutaneous injection 2.5 mg ATEOS®
Mounjaro® subcutaneous injection 5 mg ATEOS®
TirzepatideType 2 diabetes
For adults, the usual maintenance dose of Tirzepatide is 5 mg once a weekby subcutaneous injection. However, start with 2.5 mg once weekly andincrease to 5 mg once weekly after 4 weeks.
The dosage may be adjusted according to the patient's condition, but if theeffect is insufficient with 5 mg once a week, the dosage can be increasedby 2.5 mg at intervals of 4 weeks or longer. However, the maximum dosage
should be up to 15 mg once weekly.
September 26, 2022
March 15, 2023
April 18, 2023
Mounjaro® subcutaneous injection 2.5 mg ATEOS® 0.5mL 1kit: 1,924 yen
Mounjaro® subcutaneous injection 5 mg ATEOS® 0.5mL 1kit: 3,848 yen
Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

Product ImageMounjaro® subcutaneous injection 2.5 mg ATEOS

Mounjaro® subcutaneous injection 5 mg ATEOS

About Eli Lilly Japan
Eli Lilly Japan K.K. is a subsidiary of US-based Eli Lilly and Company. It contributes to medical treatment in Japan through the development, manufacture, import and sale of innovative pharmaceuticalproducts that enable people to live longer, healthier, and more fulfilling lives, focusing on the therapeutic areas such as cancer, diabetes, musculoskeletal diseases, central nervous system diseases, autoimmune diseases, growth disorder, and pain. For more information, visit http://www.lilly.co.jp

2/3

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG),
is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethicalpharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, “Forgingthe future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC isworking on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney,and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction
by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeuticmedicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravationand prognosis.For more information, go to https://www.mt-pharma.co.jp/e/3/3